Intravenous AZT does not provide extra protection against vertical transmission in mothers with undetectable viral load

Carole Leach-Lemens

Intravenous (IV)-zidovudine (AZT or ZDV) during labour and delivery is effective in reducing mother-to-child transmission (MTCT) among HIV-positive women with virological failure (viral load at or above 1000 copies/ml), even if on antiretroviral therapy (ART) during pregnancy, according to an analysis from the French Perinatal Cohort (ANRS-EPF) published in the advance online edition of Clinical Infectious Diseases.

However, for the majority (77%) with well-controlled viral load (at or under 400 copies/ml) at delivery and without obstetrical risk factors (premature rupture of membranes, preterm delivery, fever or bleeding) IV-zidovudine was not significantly associated with a lower risk of transmission.

September 23, 2013
Year of publication
AZT, PMTCT, HIV-positive women, viral load, ART, pregnancy, HIV prevention, treatment